JPRN-UMIN000015533已完成未知
Feasibility study of moderate dose of cisplatin-based chemotherapy with ultrashort hydration for advanced lung cancer - Feasibility study ofcisplatin-based chemotherapy with ultrashort hydration for advanced lung cancer
Okayama Lung Cancer Study Group0 个研究点目标入组 45 人开始时间: 2014年10月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers detected within the past 3 years. pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases pts who will receive CDDP of less than 60 mg/m²/day
研究者
相似试验
已完成
不适用
Feasibility study of moderate dose of cisplatin-based chemotherapy with short hydration for advanced lung canceradvanced lung cancerJPRN-UMIN000004493Okayama Lung Cancer Study Group45
已完成
不适用
Feasibility study of the combination of cisplatin and docetaxel with concurrent thoracic radiotherapy for locally advanced resectable non-small cell lung cancer.ocally advanced resectable non-small-cell lung cancerJPRN-UMIN000008130Hamamatsu University School of Medicine3
尚未招募
Unknown
A study to evaluate cisplatin induced hearing loss among patients of head and neck cancers receiving chemoradiation treatmentCTRI/2024/08/072465Sri Venkateshwara Institute of medical sciences
已完成
不适用
Feasibility study of cisplatin-based chemotherapy with short hydration for lung cancer patientsung cancerJPRN-UMIN000004727ational Cancer Center Hospital44
已完成
不适用
A phase I dose escalation study of cisplatin, pemetrexed and radiotherapy for inoperable stage III non-small cell lung cancerung cancerCancerLung cancerISRCTN91946477Erasmus Medical Center (The Netherlands)39